A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features

E. Trigka, G. Hardavella, A. Saetta, N. Kavantzas, P. Korkolopoulou, N. Anastasiou, E. Patsouris (Athens, Greece)

Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Session: Prognostic factors and subtyping of lung cancer
Session type: Thematic Poster Session
Number: 2923
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Trigka, G. Hardavella, A. Saetta, N. Kavantzas, P. Korkolopoulou, N. Anastasiou, E. Patsouris (Athens, Greece). A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Eur Respir J 2013; 42: Suppl. 57, 2923

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013


Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016


EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015

Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013


Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015


Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016

Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014


Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014

SMYD3 links lysine methylation of MAP3K2 to ras-driven lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015


Correlation of bim and noxa expression with clinicopathological features in NSCLC
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016

EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014

RT-PCR and IHC as the alternative methods for detection of ALK aberrations in NSCLC samples - The feasibility study
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015

Correlation of miR-422a, miR-21 and miR-155 analysis with hMSH2 and hMLH1 mRNA expression profiles in non-small cell lung carcinomas and their adjacent normal tissues
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013

Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015


Is residential radon associated with mutations in drivers genes in never smokers lung cancer cases? The case of EGFR and ALK
Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer
Year: 2016


Correlation between the simultaneus expression of HER2 and PTEN and the risk of development of metastasis in NSCLC
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016


Prevalence of molecular changes in resected pulmonary adenocarcinomas
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016


Correlation between EGFR mutations and emphysematous changes in heavy smokers with lung cancer
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013


Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013